A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

NCT00996203 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: tocilizumab [RoActemra/Actemra]
DRUG: DMARDs (disease-modifying antirheumatic drugs)

Sponsor

Hoffmann-La Roche